Tag: South Africa

Posted on

New version of i-PRO Active Guard turns VMSs into powerful search engines for real time alarm notifications and post-event searches

AI-based plug-in features industry’s largest number of search attributes, new UI enhancements and adds support for leading VMS

Tokyo, Japan, Sept. 08, 2022 (GLOBE NEWSWIRE) — i-PRO Co., Ltd., a global leader in professional security solutions for surveillance and public safety, today announced the latest version of its Active Guard plug-in. The AI-based plug-in can turn video management systems (VMS) into powerful search engines capable of real-time searches or deep forensic analysis. Already supported by leading VMSs including Genetec Security Center and i-PRO Video Insight, the latest version now adds support for Milestone Systems’ X-Protect and i-PRO’s ASM300 software, and features the industry’s largest number of search attributes and new UI enhancements.

“With the addition of Milestone X-Protect, i-PRO Active Guard is now available to the major leaders in the global VMS market and will revolutionize how Security Officers conduct real time and post event searches,” said Norio Hitsuishi, Global Head of Product Management at i-PRO. “These enhancements combined with the extension of our AI-capable camera line-up are creating a powerful end-to-end AI security ecosystem that allows businesses to take their security infrastructure to the next level. This latest announcement underscores i-PRO’s mission as a trusted next-generation partner to make AI the new standard in the security industry.”

Fast and intuitive, i-PRO Active Guard creates a more efficient and accurate AI-powered system without compromising on image quality or network performance. The plug-in integrates seamlessly into the existing UI of the VMS, appearing as just another function tab. It allows users to easily manage the AI analytics from multiple i-PRO cameras and allows users to easily set up sophisticated search parameters based on the industry’s largest number of search attributes which include gender, age, clothing color, facial characteristics, vehicle color and direction, and many more.

With Active Guard, Security Officers no longer have to spend time looking at multiple screens for persons or vehicles of interest or watch hours of recorded video to search for important events. Operators can register specific characteristics in their watch lists (for instance “male wearing a red shirt and blue pants”) and the VMS will send them a real-time alarm whenever a match is identified, a feature that is unique to i-PRO. This enhances real-time situational awareness and enables proactive security. The same process can be set up for fast data mining of events during forensic investigations.

The metadata is captured and analyzed by i-PRO AI network cameras at the edge, which use the powerful Ambarella SoC, reducing bandwidth and eliminating the need for expensive servers. i-PRO Active Guard is a light-load and unique in the industry in that the edge-processed AI data results are sent to the Active Guard server eliminating the requirement for additional on-premises servers. The metadata is then searched and presented in the Active Guard plugin on the client.

For more information, visit

https://i-pro.com/global/en/surveillance/featured-products/i-pro-active-guard

About i-PRO

i-PRO Co., Ltd., is a global leader of advanced sensing technologies in the fields of Intelligent Surveillance, Public Safety and Industrial/Medical Imaging. Established in 2019, i-PRO was built on a legacy of over 60 years of innovation with Panasonic. The company’s products, software and services extend human senses to capture moments of truth with innovations that inform and protect. In order to help create a safer world, i-PRO Co., Ltd., supports the work of professionals who protect and save lives.

© i-PRO is a trademark of i-PRO Co., Ltd. Other trademarks used in this document may be trademarks of the manufacturers or vendors of the respective product.

Attachments

Veronique Froment
i-PRO
603-537-9248
veronique@Highrezpr.com
Posted on

Huawei Cloud Meeting Facilitates Shenzhou-14 Taikonaut Talk with African Youth

SHENZHEN, China, Sept. 8, 2022 /PRNewswire/ — Three Shenzhou-14 Chinese astronauts (taikonauts), who are currently in space, took part in a dialogue with students from several African countries via video link on September 6. Behind the success of this globally livestreamed event was the unwavering support provided by Huawei Cloud Meeting, which ensured a smooth video connection between all participants.

This year marks the 20th anniversary of the establishment of diplomatic relations between China and the African Union. The activity, co-hosted by the Mission of China to the African Union, China Manned Space Agency (CMS) and the African Union Commission (AUC), was one of the activities organized to celebrate the occasion. It was the first time that the taikonauts had a direct dialogue with African teenagers.

Teenagers from Algeria, Egypt, Ethiopia, Namibia, Nigeria, Senegal, Somalia and South Africa had the opportunity to ask the three taikonauts questions. Taikonauts Chen Dong, Liu Yang, and Cai Xuzhe are currently on a mission at the Tiangong space station, and the trio answered questions on life in space, scientific experiments, and the growth that they have experienced.

The global network SparkRTC ensured stable real-time HD video connections for both the on-site and online meeting participants in China and the aforementioned African countries. Simultaneous interpretation between Chinese, English, and French allowed everyone to express their ideas easily and better understand one other. Diverse meeting control functions ensured that the event proceeded in an orderly manner. The professional end-to-end assurance and global service team of Huawei Cloud smoothened video connections.

Huawei Cloud Meeting ensures stable access from 170+ countries and regions. It has a proven track record of being featured at over 500 international conferences and earns the trust of more than 1.5 million customers in both private and public sectors. The professional cloud meeting solution helps organizations go digital and improve efficiency.

Photo – https://mma.prnewswire.com/media/1893524/20220907_193008_WeLinkPC__ID_6a6b83e3ad7c.jpg

Posted on

MORA Enters South Africa, Debuts Bar Fridges for Joy and Life

CAPE TOWN, South Africa, Sept. 8, 2022 /PRNewswire/ — MORA, a pioneering household appliance brand owned by Hisense Group, takes a milestone to officially launch its presence in South Africa by introducing three bar-fridge products to its local consumers in September. The first step to fulfilling the essentials for a high-quality life, MORA presents its function, technology, and design to take care of the well-being of South African families with the vision of “full of joy, full of life”.

MORA, with a rich history that can be traced back to 1825 in the Czech Republic, takes the step into South Africa to join the Hisense brand, intending to meet the needs of South African households. By launching a series of must-have accessories which come with A+ energy efficiency features and low noise design, including the M65RTS that is already in store, as well as the M125RT and M125RWH coming soon to the market, MORA takes its path to become that can be a reliable helper and a natural centrepiece of its consumer’s kitchen.

The introduction of the must-have bar fridges echoes MORA’s commitment to making life easier and fun for its South African consumers. The bar fridges apply low noise design and energy-saving technologies with different capacities and colours available, making them versatile with the potential in fitting into multiple parts of daily life. From individuals living in limited space to business professionals, the bar fridges can enable an entertaining lifestyle in many ways.

Using MORA’s products, South African families can not only enjoy its product’s performance, reliability, comfort and simplicity but also in many scenarios from equipping the cottages to decorating suites or flats used for business purposes.

Entry to South Africa marks a step further MORA’s ultimate aim to accomplish daily tasks for its consumers while living important moments and experiences with the family. Its advanced technologies innovate home appliances to apply economical and environmentally friendly modern functions.

MORA has been a part of the modern kitchen since its inception. By sharing its experience and innovation with its consumers in South Africa, MORA will support South African families’ in-home cooking and help create moments that are fun, light-hearted, and adventurous in their life.

MORA’s products will be available through multiple channels, including distributors and stores such as OK and HNH. Find more at https://hisense.co.za/mora/.

Photo – https://mma.prnewswire.com/media/1894631/image_5020023_43307694.jpg

Posted on

The $1.19 trillion USD lost to the global economy due to illiteracy dubbed “the hidden impact of the pandemic.”

For a country by country breakdown visit https://worldliteracyfoundation.org/

LONDON, Sept. 7, 2022 /PRNewswire/ — On International Literacy Day (September 8 2022) a new report has highlighted the economic cost and social impact of a spike in illiteracy rates due to the disruption in children’s education caused by the pandemic.

World Literacy Foundation (WLF) CEO Andrew Kay said, “The study finds that children from low-income homes are those most impacted in a post-pandemic environment. With gaps in their reading development, many children face lifelong illiteracy without effective intervention”.

Released today on International Literacy Day to highlight the impact of illiteracy caused by the COVID-19 pandemic, the Foundation’s report titled “The Economic & Social Cost of Illiteracy” says illiteracy is costing the global economy $1.19 trillion USD. Report available here: https://worldliteracyfoundation.org/

Mr Kay said, “illiteracy traps young people in an endless cycle of poverty and life-long hardship, often unable to fill out a form, read a street sign or a medicine label”.

“The problem of illiteracy is often hidden by the person yet linked to numerous negative social and financial outcomes”.

“Globally, almost 770 million people can’t read a single word and another 2 billion people struggle to read a sentence.

As we observe International Literacy Day 2022, we must hold our political leaders to account, asking that they urgently remedy these catastrophic statistics.

“In both developing and developed countries, illiteracy is ruining lives and is linked with an array of poor life outcomes, such as poverty, inequity, unemployment, social exclusion, crime and long-term illness.

“We need to understand that early intervention can avert a lifetime of hardship, poverty and pain for a child, young person or adult who is struggling to read or write.

“Rapid change in digital technology is changing the landscape and ability of the populations in the poorest countries to learn to read and write. New and exciting opportunities are opening almost every day,” Mr Kay concluded.

Posted on

Tribert Rujugiro Ayabatwa se félicite de la décision de la Cour de justice de l’Afrique de l’Est selon laquelle la saisie par le gouvernement rwandais du centre commercial Union Trade Centre était illégale

TORONTO, 7 septembre 2022 /PRNewswire/ — L’entrepreneur et philanthrope Tribert Rujugiro Ayabatwa est heureux d’annoncer que le 30 août 2022, la Cour de justice de l’Afrique de l’Est (EACJ, East African Court of Justice) a statué que la saisie et la vente aux enchères par le gouvernement rwandais de son centre commercial Union Trade Centre (UTC) étaient illégales. L’EACJ a accordé à M. Ayabatwa 1 million de dollars US, 6 % d’intérêts et les frais de justice. Le gouvernement a saisi le centre commercial de 20 millions de dollars en 2013, en alléguant que l’UTC avait été « abandonné » parce que M. Ayabatwa, qui est né au Rwanda, résidait hors du pays. L’UTC était à l’époque une entreprise florissante, accueillant 80 entreprises avec près de 500 employés, gérée par une solide équipe locale en règle avec les autorités rwandaises. Puis, en août 2015, le gouvernement a déclaré l’UTC défaillant fiscal à hauteur de 1,4 million de dollars, une affirmation absurde, puisque le centre commercial était géré par l’État rwandais. Deux ans plus tard, le gouvernement a vendu l’UTC aux enchères pour la modique somme de 8 millions de dollars, soit moins de la moitié de sa valeur réelle.

Union Trade Centre Mall

M. Ayabatwa a porté le gouvernement devant l’EACJ, qui a statué en 2020 que la saisie et la mise aux enchères d’UTC étaient illégales. Il a été ordonné au gouvernement de rendre compte des produits de la location et de la vente d’UTC depuis 2013 et d’indemniser M. Ayabatwa pour des dommages s’élevant à 500 000 dollars et des intérêts annuels de 6 % à compter de la date du jugement. M. Ayabatwa a toutefois fait appel du jugement, car la Cour ne lui a pas restitué la propriété d’UTC. C’est alors que le gouvernement a fabriqué une nouvelle allégation absurde selon laquelle M. Ayabatwa et ses associés avaient détourné 458 058 dollars d’UTC en 2011. Le « crime » cité était en fait un prêt contracté pendant la construction du centre commercial UTC. Aujourd’hui, le gouvernement rwandais a une fois de plus perdu l’affaire du centre commercial UTC. M. Ayabatwa a salué la décision de la Cour du 30 août 2022, en faisant remarquer « qu’il y a des moments où nous sommes impuissants face à l’injustice, mais avec la vérité de votre côté, la justice prévaut toujours ».

À propos de Tribert Rujugiro Ayabatwa

Tribert Rujugiro Ayabatwa est un entrepreneur et un philanthrope rwandais accompli. Il est le fondateur du Pan-African Tobacco Group, le plus grand fabricant indigène de produits du tabac en Afrique, présent dans neuf pays africains et aux Émirats arabes unis, et dont les activités commerciales couvrent l’Afrique orientale, occidentale et australe. M. Ayabatwa est l’un des principaux philanthropes d’Afrique. Il aide les communautés à progresser en matière de sécurité alimentaire, d’accès à l’eau potable, de reforestation, d’éducation et de stages en ingénierie.

Pan-African Tobacco Group

info@ptg-hld.com

www.ptg-hld.com

Photo – https://mma.prnewswire.com/media/1892959/Tribert_Rujugiro_Ayabatwa__UTC_founder_Tribert_Rujugiro_Ayabatwa.jpg

David Himbara, Pan-African Tobacco Group, info@ptg-hld.com, www.ptg-hld.com

Posted on

Zenas BioPharma nomme Simon Lowry, M.D. au poste de directeur médical

WALTHAM, Mass. et SHANGHAI, Chine, 07 sept. 2022 (GLOBE NEWSWIRE) — Zenas BioPharma, une société biopharmaceutique mondiale déterminée à devenir un leader dans le développement et la commercialisation de thérapies immunitaires pour les patients dans le besoin à travers le monde, a annoncé aujourd’hui la nomination de Simon Lowry, M.D., au poste de directeur médical de la société. Le Dr Lowry apporte plus de 20 ans d’expertise clinique dans la conception et l’exécution de programmes cliniques de stade précoce à avancé à Zenas, où il dirigera les fonctions cliniques, médicales et de pharmacovigilance de la société au niveau international.

« Nous sommes ravis d’accueillir le Dr Lowry au sein de Zenas à ce moment crucial pour la société, alors que nous commençons deux essais d’enregistrement de phase trois pour notre principal produit candidat, l’obexelimab, au quatrième trimestre de cette année, et que nous entamons les premiers essais cliniques sur l’homme pour plusieurs programmes en cours », a déclaré Hua Mu, M.D., Ph. D, président-directeur général de Zenas. « Le leadership éprouvé du Dr Lowry, sa vaste expérience du développement clinique et sa grande expérience en matière d’essais cliniques à l’échelle mondiale renforceront davantage notre capacité à mener à bien notre mission, qui consiste à transformer la vie des patients dont les besoins médicaux ne sont pas satisfaits, en leur proposant les meilleurs traitements immunitaires de leur catégorie. »

Le Dr Simon Lowry a ajouté : « De nombreux patients atteints de maladies rares et auto-immunes ont besoin d’options thérapeutiques nouvelles et efficaces. L’équipe de Zenas, très expérimentée et talentueuse, a considérablement développé son portefeuille en très peu de temps, et je suis impatient de diriger l’avancement continu des programmes cliniques de Zenas jusqu’à la commercialisation, tout en renforçant le portefeuille de programmes innovants de la société. »

Le Dr Lowry est un médecin possédant 20 ans d’expérience dans des sociétés pharmaceutiques et biotechnologiques importantes et émergentes, où il a dirigé des programmes de développement fructueux, des équipes d’affaires cliniques et médicales, et interagi avec des organismes de réglementation dans plusieurs domaines de la médecine, y compris la rhumatologie, l’immunologie et l’ophtalmologie. Avant de rejoindre Zenas, le Dr Lowry était directeur médical chez Kinevant Science, une société biopharmaceutique au stade clinique, spécialisée dans le traitement des maladies inflammatoires et auto-immunes rares. Le Dr Lowry était auparavant responsable de la R&D en immunologie chez Roivant Sciences, où il dirigeait tous les actifs de l’immunologie en phase de développement clinique, et était un membre clé de l’équipe de direction. Il a également occupé le poste de directeur médical chez Sun Pharma North America, où il était responsable de quatre domaines thérapeutiques de marque (immunologie et dermatologie, ophtalmologie, neurologie et oncologie), et a dirigé tous les aspects du développement et des fonctions médicales (y compris le développement clinique, les informations médicales, la médecine de terrain, La recherche sur l’économie et les résultats de la santé (HEOR), les publications/communications médicales et les opérations). Au début de sa carrière, il a travaillé chez Novartis, où il a occupé le poste de vice-président, directeur de franchise des affaires médicales mondiales, immunologie et dermatologie, et chez Pfizer, où il a occupé des postes à responsabilité croissante, notamment celui de vice-président du groupe des affaires médicales en oncologie.

Avant sa carrière dans le secteur pharmaceutique/biotechnologique, le Dr Lowry a pratiqué la médecine interne dans diverses institutions au Royaume-Uni et en Australie. Il a obtenu son BA au Trinity Hall, de l’université de Cambridge, au Royaume-Uni et son diplôme médical MB BChir à la Cambridge University School of Clinical Medicine.

À propos de Zenas BioPharma

Zenas BioPharma est une société biopharmaceutique mondiale déterminée à devenir un leader dans le développement et la commercialisation de traitements immunitaires pour les patients dans le monde entier. Avec un développement clinique et des activités aux États-Unis et en Chine, Zenas fait rapidement progresser un important programme de traitements innovants qui continue de s’accroître grâce à notre stratégie de développement commercial fructueuse. Notre équipe de direction expérimentée et notre réseau de partenaires commerciaux stimulent l’excellence opérationnelle pour apporter des thérapies potentiellement transformatrices afin d’améliorer la vie des personnes confrontées à des maladies rares et auto-immunes. Pour tout complément d’information sur Zenas BioPharma, veuillez consulter le site www.zenasbio.com et nous suivre sur Twitter à l’adresse @ZenasBioPharma et LinkedIn.

Contact auprès des investisseurs et des médias :
Joe Farmer
Zenas BioPharma
IR@zenasbio.com

Posted on

Zenas BioPharma Appoints Simon Lowry, M.D. as Chief Medical Officer

WALTHAM, Mass. and SHANGHAI, China, Sept. 07, 2022 (GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients in need around the world, today announced the appointment of Simon Lowry, M.D., as the company’s Chief Medical Officer. Dr. Lowry brings over 20 years of broad clinical expertise in the design and execution of early to late-stage clinical programs to Zenas, where he will lead the company’s global clinical, medical affairs, and pharmacovigilance functions.

“We are delighted to welcome Dr. Lowry to Zenas at this pivotal time for the company as we commence two phase three registration trials for our lead product candidate, obexelimab, in the fourth quarter of this year and initiate first-in-human clinical trials for multiple pipeline programs,” said Hua Mu, M.D., Ph. D, Chief Executive Officer at Zenas. “Dr. Lowry’s proven leadership, broad clinical development background, and extensive global clinical trial experience will further strengthen our ability to execute on our mission to transform the lives of patients with unmet medical needs by bringing best-in-class immune-based therapies to patients.”

Dr. Simon Lowry added, “There are many patients with autoimmune and rare diseases in need of effective new treatment options. The deeply experienced and talented Zenas team has made impressive progress advancing the company’s pipeline in a very short period of time, and I look forward to leading the ongoing advancement of Zenas’ clinical programs through commercialization while further expanding the company’s pipeline of innovative programs.”

Dr. Lowry is a medical doctor with 20 years of experience at large and emerging pharmaceutical and biotechnology companies directing successful development programs, leading clinical and medical affairs teams, and interacting with regulatory agencies across multiple areas of medicine, including rheumatology, immunology, and ophthalmology. Prior to joining Zenas, Dr. Lowry was Chief Medical Officer at Kinevant Science, a clinical-stage biopharmaceutical company focused on treating rare inflammatory and autoimmune diseases. Dr. Lowry was previously Head of Immunology R&D at Roivant Sciences, leading all development stage immunology assets into clinical development, and served as a key member of the leadership team. He also served as Chief Medical Officer at Sun Pharma North America, where he was responsible for four branded therapeutic areas (Immunology & Dermatology, Ophthalmology, Neurology and Oncology), and led all aspects of development and medical functions (including clinical development, medical information, field medical, HEOR, publications / medical communications, and operations). Early in his career, he worked at Novartis, where he served as Vice President, Global Medical Affairs Franchise Head, Immunology & Dermatology, and Pfizer, where he served in roles of increasing responsibility, including as Vice President, Oncology Medical Affairs Group Leader.

Prior to his pharmaceutical/ biotechnology career, Dr. Lowry practiced internal medicine at various institutions in the UK and Australia. He received his BA from Trinity Hall, Cambridge University, UK and his MB BChir medical degree from Cambridge University School of Clinical Medicine.

About Zenas BioPharma

Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients around the world. With clinical development and operations in the US and China, Zenas is rapidly advancing a deep pipeline of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn.

Investor and Media Contact:
Joe Farmer
Zenas BioPharma
IR@zenasbio.com

Posted on

Zenas BioPharma Nomeia Simon Lowry, M.D. para Diretor Médico

WALTHAM, Mass. e SHANGHAI, China, Sept. 07, 2022 (GLOBE NEWSWIRE) — A Zenas BioPharma, uma empresa biofarmacêutica global comprometida em se tornar líder no desenvolvimento e comercialização de terapias imunológicas, anunciou hoje a nomeação de Simon Lowry, MD para seu Conselho Diretor. O Dr. Lowry tem mais de 20 anos de ampla experiência clínica na concepção e execução de programas clínicos de estágio inicial a final na Zenas, onde ele passará a liderar as funções globais de clínica, assuntos médicos e farmacovigilância da empresa.

“Estamos muito contentes em receber o Dr. Lowry na Zenas neste momento crucial para a empresa, quando damos início a dois testes de registro de fase três do nosso principal candidato a produto, obexelimabe, no quarto trimestre deste ano, e aos primeiros testes clínicos em humanos de vários programas de pipeline”, disse Hua Mu, M.D., Ph.D., Diretor Executivo da Zenas. “A liderança comprovada do Dr. Lowry, seu amplo histórico de desenvolvimento clínico e extensa experiência com ensaios clínicos globais irão fortalecer ainda mais nossa capacidade de executar nossa missão de transformar a vida dos pacientes com necessidades médicas não atendidas, com a oferta das melhores terapias imunológicas aos pacientes.”

O Dr. Simon Lowry acrescentou: “Há muitos pacientes com doenças autoimunes e raras que precisam de novas opções de tratamento eficazes. A equipe profundamente experiente e talentosa da Zenas fez um progresso impressionante ao avançar no pipeline da empresa em um período muito curto de tempo, e estou pronto para liderar o avanço contínuo dos programas clínicos da Zenas com a sua comercialização e maior expansão do pipeline de programas inovadores da empresa.”

O Dr. Lowry tem 20 anos de experiência com grandes empresas farmacêuticas e de biotecnologia emergentes, tendo dirigido programas de desenvolvimento bem-sucedidos, liderado equipes de assuntos clínicos e médicos, e interagido com agências reguladoras em várias áreas da medicina, incluindo reumatologia, imunologia e oftalmologia. Antes de ingressar na Zenas, o Dr. Lowry foi Diretor Médico da Kinevant Science, uma empresa biofarmacêutica de estágio clínico focada no tratamento de doenças inflamatórias e autoimunes raras. Anteriormente, o Dr. Lowry foi Chefe de Pesquisa e Desenvolvimento em Imunologia da Roivant Sciences, liderando todos os ativos de imunologia em estágio de desenvolvimento para o desenvolvimento clínico, e serviu como um membro-chave da equipe de liderança. Ele também atuou como Diretor Médico na Sun Pharma North America, onde foi responsável por quatro áreas terapêuticas de marca (Imunologia e Dermatologia, Oftalmologia, Neurologia e Oncologia) e liderou todos os aspectos do desenvolvimento e funções médicas (incluindo desenvolvimento clínico, informações médicas, medicina de campo, HEOR, publicações/comunicações médicas e operações). No início da sua carreira, ele trabalhou na Novartis, onde atuou como Vice-Presidente, Chefe de Franquia de Assuntos Médicos Globais, Imunologia e Dermatologia, e na Pfizer, onde atuou em funções de responsabilidade crescente, incluindo como Vice-Presidente, Líder do Grupo de Assuntos Médicos de Oncologia.

Antes da sua carreira farmacêutica/biotecnológica, o Dr. Lowry exerceu medicina interna em várias instituições no Reino Unido e na Austrália. Ele é formado em Medicina pela Trinity Hall, Cambridge University e pela Cambridge University School of Clinical Medicine no Reino Unido.

Sobre a Zenas BioPharma

A Zenas BioPharma é uma empresa biofarmacêutica mundial comprometida em se tornar líder global no desenvolvimento e comercialização de terapias imunológicas para pacientes em todo o mundo. Com desenvolvimento clínico e operações nos EUA e na China, a Zenas está avançando rapidamente um vasto pipeline de terapêuticas inovadoras que continua a crescer por meio da nossa estratégia de desenvolvimento de negócios de sucesso. Nossa experiente equipe de liderança e rede de parceiros de negócios impulsionam a excelência operacional para oferecer terapias potencialmente transformadoras para melhorar a vida das pessoas que enfrentam doenças autoimunes e raras. Para mais informação sobre a Zenas BioPharma, visite www.zenasbio.com e siga-nos no Twitter em @ZenasBioPharma e LinkedIn.

Contato com Investidores e com a Mídia:
Joe Farmer
Zenas BioPharma
IR@zenasbio.com